The Sackler Family and the Opioid Crisis

The Sackler family, owners of Purdue Pharma, aggressively marketed OxyContin while downplaying addiction risks, contributing to an opioid crisis that killed over 500,000 Americans. The controversy centers on internal documents showing the family knew about abuse potential, their influence over pain treatment guidelines, bankruptcy maneuvers shielding billions in personal wealth, and the ethical implications of their philanthropy.

• court filingpartial redactionDOC-A1
  Massachusetts Attorney General's Complaint Against Purdue Pharma and Sackler Family (2018)

  This complaint included internal Purdue emails and documents showing Richard Sackler and other family members directly participated in marketing decisions, knew about OxyContin abuse patterns, and continued aggressive sales strategies. The filing revealed the family extracted $10.7 billion from Purdue between 2008-2018. Represents primary documentary evidence of family involvement beyond passive ownership.

• documentDOC-A2
  DOJ Purdue Pharma Criminal Resolution Documents (2020)

  Official Department of Justice records documenting Purdue's guilty pleas to conspiracy to defraud the United States and violating anti-kickback laws, including $8.3 billion in penalties. Notable for holding the corporation criminally liable while not charging individual Sackler family members despite evidence of their knowledge and involvement.

• court filingDOC-A3
  Bankruptcy Court Settlement Agreement and Third-Party Release Provisions (2021)

  The approved bankruptcy plan that granted Sackler family members immunity from future civil opioid litigation in exchange for $6 billion payment over nine years. This document became the center of legal controversy regarding whether bankruptcy courts can shield non-bankrupt third parties from civil liability without unanimous consent.

• dataDOC-A4
  CDC Opioid Overdose Death Statistics (1999-2023)

  Government epidemiological data showing prescription opioid deaths rose from 3,442 in 1999 to peak involvement in the overdose crisis, with over 500,000 total opioid deaths through 2023. Provides quantitative context for the scale of the public health crisis, though deaths increasingly involve illicit fentanyl rather than prescription opioids alone.

• documentpartial redactionDOC-A5
  FDA OxyContin Approval Documents and Label Changes (1995-2010)

  Original FDA approval materials for OxyContin showing the initial label claimed "delayed absorption, as provided by OxyContin tablets, is believed to reduce the abuse liability." Later label revisions removed addiction-minimizing language. Documents the regulatory basis for Purdue's marketing claims and subsequent corrections.

• testimonypartial redactionDOC-A6
  Richard Sackler Deposition Testimony in State Litigation (2015-2019)

  Sealed and later released depositions showing Richard Sackler's testimony about his role in OxyContin marketing, his knowledge of abuse issues, and his response to the growing crisis. His statements under oath became key evidence in establishing family members' direct involvement versus claims they were merely passive investors.

• documentheavy redactionDOC-A7
  Purdue Internal Sales Strategy Documents (2001-2016)

  Internal company records revealed through litigation showing bonus structures for sales representatives based on prescription volume, targeting of high-prescribing physicians, and strategies to overcome concerns about addiction. Demonstrates systematic approach to maximizing sales despite growing evidence of abuse and diversion.

• otherDOC-A8
  Supreme Court Decision: Harrington v. Purdue Pharma L.P. (2024)

  The 5-4 Supreme Court ruling that bankruptcy courts lack authority to grant legal immunity to non-debtor third parties (the Sacklers) over the objection of affected parties. Justice Gorsuch's majority opinion found such releases exceed bankruptcy court jurisdiction, forcing renegotiation of the settlement and eliminating the Sackler family's liability shield.